a Faculty of Pharmacy , Tabriz University of Medical Sciences , Tabriz , Iran.
b Department of Chemistry , Payame Noor University , Tehran , Iran.
J Biomater Sci Polym Ed. 2018 Aug;29(11):1265-1286. doi: 10.1080/09205063.2018.1456026. Epub 2018 Apr 9.
A Novel poly [2-hydroxyethyl methacrylate-Lactide-dimethylaminoethyl methacrylate quaternary ammonium alkyl halide] [P(HEMA-LA-MADQUAT)] copolymer was synthesized through combination of ring opening polymerization (ROP) and 'free' radical initiated polymerization methods. This newly developed copolymer was fully characterized by FT-IR, HNMR and CNMR spectroscopy. Micellization of the copolymer was performed by dialysis membrane method and obtained micelles were characterized by FESEM, dynamic light scattering (DLS), zeta potential (ξ), and critical micelle concentration (CMC) measurements. This copolymer was developed with the aim of co-delivering two different anticancer drugs: methotrexate (MTX) and chrysin. In vitro cytotoxicity effect of MTX@Chrysin-loaded P(HEMA-LA-MADQUAT) was also studied through assessing the survival rate of breast cancer cell line (MCF-7) and DAPI staining assays. Cationic micelle (and surface charge of + 7.6) with spherical morphology and an average diameter of 55 nm and CMC of 0.023 gL was successfully obtained. Micelles showed the drug loaded capacity around 87.6 and 86.5% for MTX and Chrysin, respectively. The cytotoxicity assay of a drug-free nanocarrier on MCF-7 cell lines indicated that this developed micelles were suitable nanocarriers for anticancer drugs. Furthermore, the MTX@Chrysin-loaded micelle had more efficient anticancer performance than free dual anticancer drugs (MTX @ chrysin), confirmed by MTT assay and DAPI stainingmethods. Therefore, we envision that this recently developed novel micelle can enhance the efficacy of chemotherapeutic agents, MTX and Chrysin, combination chemotherapy and has the potential to be used as an anticancer drug delivery system for in vivo studies. Therefore, this recently developed novel micelle can enhance the efficacy of chemotherapeutic agents, MTX and Chrysin, combination chemotherapy and has the potential to be used as an anticancer drug delivery system for in vivo studies.
一种新型聚[2-羟乙基甲基丙烯酸酯-乳酸-二甲氨基乙基甲基丙烯酸酯季铵卤化物] [P(HEMA-LA-MADQUAT)]共聚物通过开环聚合(ROP)和“自由”基引发聚合方法的结合合成。通过傅里叶变换红外光谱(FT-IR)、HNMR 和 CNMR 光谱对新开发的共聚物进行了充分的表征。通过透析膜法进行共聚物的胶束化,通过 FESEM、动态光散射(DLS)、zeta 电位(ξ)和临界胶束浓度(CMC)测量对获得的胶束进行了表征。该共聚物的开发旨在共同递送两种不同的抗癌药物:甲氨蝶呤(MTX)和白杨素。还通过评估乳腺癌细胞系(MCF-7)的存活率和 DAPI 染色试验研究了 MTX@白杨素负载的 P(HEMA-LA-MADQUAT)的体外细胞毒性作用。成功获得了带正电荷的胶束(表面电荷为+7.6),具有球形形态,平均直径为 55nm,CMC 为 0.023gL。胶束对 MTX 和白杨素的载药量分别约为 87.6%和 86.5%。对 MCF-7 细胞系的无药物纳米载体的细胞毒性测定表明,这种开发的胶束是适用于抗癌药物的纳米载体。此外,MTX@白杨素负载的胶束比游离的双抗癌药物(MTX@白杨素)具有更高的抗癌效果,这通过 MTT 测定和 DAPI 染色方法得到证实。因此,我们设想这种新开发的新型胶束可以增强化疗药物 MTX 和白杨素的疗效,联合化疗,并有可能作为体内研究的抗癌药物递送系统。因此,这种新开发的新型胶束可以增强化疗药物 MTX 和白杨素的疗效,联合化疗,并有可能作为体内研究的抗癌药物递送系统。
J Biomater Sci Polym Ed. 2017-12-15
Int J Nanomedicine. 2013-4-16
Int J Pharm. 2018-12-15
Pharmaceuticals (Basel). 2025-8-5
Front Pharmacol. 2023-9-12
Pharmaceutics. 2022-12-13
Cancer Cell Int. 2021-4-15